Oruka Therapeutics, Inc. (ORKA) Stock: Price, Forecast & Analyst Target
Oruka Therapeutics, Inc. (ORKA) — MoonshotScore 66/100 (Strong band), calculated Oct 26, 2026. Price $90.33 (+12.70%), as of the Oct 26, 2026 trading session; market cap $5.98B. Expected results Nov 11, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 6.85× (market value Oct 26, 2026; cash Jun 30, 2026) · expected results Nov 11, 2026
Oruka Therapeutics, Inc. · ORKA · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Oruka Therapeutics is a clinical-stage antibody developer focused on psoriasis and related inflammatory disease, with lead programs aimed at distinct interleukin pathways and a sequential regimen that combines them. It has no product revenue, so the case depends on whether clinical progress can turn a well-funded research portfolio into a commercial franchise before rising development spending erodes that advantage.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · Oruka Therapeutics (ORKA)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but stalling growth; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Surging.
- EPS beat 6 of 8
- ROE -20.8% · ROA -11.7% · current ratio 38.51 · earnings yield -2.9% · free-cash-flow yield -2.1%
Holding back: soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 66 | Strong | |
| 70 | Strong | |
| 66 | Strong | |
| 71 | Strong | |
| 66 | Strong | |
| 66 | Strong |
The score was 66 in the stored Oct 24, 2026 snapshot and remains 66 in the current publication computed Oct 26, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $90.33 | |
| Change on the day | +12.70% | |
| 52-week range | $25.23–$115.52 | |
| Market capitalisation | $5.98B | |
| Shares traded on the day | 1.94M | |
| Beta (volatility vs the S&P 500) | -0.39 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Oruka Therapeutics (ORKA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 22, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 26, 2026, except a card that shows its own read date.
Watch the ORKA film — every key number, told as a short cinematic story
~2 min · open the film
What is Oruka Therapeutics (ORKA), and what does it report?
Short answer · as of
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Research dated 2026-09-13.
Oruka does not yet sell medicines. It develops monoclonal antibodies for psoriasis and related inflammatory conditions, including a candidate directed at an interleukin p-subunit pathway, an antibody addressing the A and F forms of another interleukin, and a sequential regimen using those programs.
Its reported numbers therefore measure the cost of advancing candidates rather than customer demand. Research and development dominates operating expense, revenue remains absent, and capital expenditure is negligible beside operating cash use.
What do the latest results show for Oruka Therapeutics (ORKA)?
Short answer · as of
Against analyst estimates the company has EPS beat 6 of 8 reports.
Research dated 2026-09-13.
The latest reported period brought a sharp increase in research and development spending, while administrative expense eased slightly. Operating loss widened, net loss grew, and cash used in operations increased.
The mechanism visible in the accounts is straightforward: additional research spending outweighed the modest administrative relief. That deterioration reflects heavier program investment, but it does not establish clinical efficacy; separately, the latest reported earnings result was slightly worse than expected after a run of outcomes that generally exceeded estimates.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · R&D
- $43.26M Jun 30, 2026
- Latest quarter · SG&A
- $6.81M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$50.11M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | $43.26M | $6.81M | −$50.11M |
| Mar 31, 2026 | Not available | $29.14M | $7.25M | −$36.43M |
| Dec 31, 2025 | Not available | $27.64M | $6.76M | −$34.43M |
| Sep 30, 2025 | Not available | $28.99M | $5.12M | −$34.10M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · EPS vs estimate
- Below estimate Aug 10, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 10, 2026 | Not available | Not available | −$0.5500 | −$0.5125 |
| May 13, 2026 | Not available | Not available | −$0.4800 | −$0.5469 |
| Mar 12, 2026 | Not available | Not available | −$0.4500 | −$0.6100 |
| Nov 12, 2025 | Not available | Not available | −$0.5500 | −$0.5600 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
What are the financial strengths and risks for Oruka Therapeutics (ORKA)?
Short answer
Cash and short-term investments were $873.56M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$33.15M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and investments tower over debt and total liabilities, while short-term liquidity alone supports a long runway at the recently annualized burn rate. The balance sheet gives Oruka substantial room to advance its antibody portfolio without near-term dependence on operating revenue.
The vulnerability is that the burn rate is moving higher alongside research spending. A runway extrapolation can shorten if trials expand or development costs accelerate, and clinical failure would leave no commercial revenue to absorb the cost base; because the market value stands well above net cash, the equity outcome is not limited to changes in cash.
Data-derived red flags
- Negative return on equity (-20.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$33.15M Jun 30, 2026
- Previous quarter · operating cash flow
- −$23.58M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$33.15M | $0.00 |
| Mar 31, 2026 | −$23.58M | −$70,000 |
| Dec 31, 2025 | −$22.59M | −$60,000 |
| Sep 30, 2025 | −$21.60M | −$100,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Oruka Therapeutics (ORKA)?
Short answer · as of
The next earnings report is expected on Nov 11, 2026. The number it tests is the $-2.40 EPS analysts carry for it.
Research dated 2026-09-13.
At the scheduled earnings update, watch whether research spending and operating cash use continue rising together, and whether the enlarged liquidity balance remains intact. The relationship between those measures will show how quickly program expansion is consuming the financing cushion.
Changes in the status of the distinct lead antibodies and the sequential regimen matter more than a narrow earnings beat or miss. Revenue expectations remain absent through most of the forecast horizon, so clinical advancement and spending discipline remain the useful operating signals.
What the records here don't tell us
- No quarterly income statement is held for ORKA.
Checked against the records this page reads, on the dates shown above.
How does Oruka Therapeutics compare with its peers?
Short answer
Oruka Therapeutics's score ranks tied for 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Oruka differs from a commercial biotechnology company because there is no sales base, gross-margin profile, or established demand curve to compare. Its distinguishing feature among clinical-stage immunology developers is a portfolio spanning separate interleukin mechanisms plus a sequential regimen built from its own antibody programs, rather than dependence on a lone standalone candidate.
That design creates alternative development paths but keeps the portfolio concentrated in psoriasis and related inflammatory conditions. Comparisons with similar businesses are therefore most meaningful through clinical progress, liquidity, and the rate of research spending rather than conventional revenue growth.
| Company | Price | Market value | Score |
|---|---|---|---|
| $312.93 Oct 26, 2026 | $9.26B | 98 5-pillar Oct 26, 2026 | |
| $303.53 Oct 23, 2026 | $6.05B | 96 5-pillar Oct 26, 2026 | |
| $47.93 Oct 23, 2026 | $3.85B | 96 5-pillar Oct 26, 2026 | |
| $43.74 Oct 26, 2026 | $3.92B | 95 5-pillar Oct 26, 2026 | |
| $31.20 Oct 23, 2026 | $3.92B | 92 5-pillar Oct 26, 2026 | |
| $32.23 Oct 26, 2026 | $9.11B | 91 5-pillar Oct 26, 2026 | |
| $86.31 Oct 26, 2026 | $9.33B | 86 5-pillar Oct 26, 2026 | |
| $140.32 Oct 26, 2026 | $9.08B | 75 5-pillar Oct 26, 2026 | |
| $143.35 Oct 26, 2026 | $5.77B | 68 5-pillar Oct 26, 2026 | |
| $54.79 Oct 26, 2026 | $8.39B | 67 5-pillar Oct 26, 2026 | |
| Oruka Therapeutics (ORKA) — this page | $90.33 | $5.98B | 66 |
| $137.39 Oct 26, 2026 | $5.74B | 66 5-pillar Oct 26, 2026 | |
| $44.44 Oct 26, 2026 | $7.46B | 66 5-pillar Oct 26, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $120.00 – $200.00
- Consensus target
- $144.56
- Median target
- $130.00
- Revenue estimate
- $0.00
- EPS estimate
- $-2.40
Consensus record · Captured .
Measured against a quoted price of $90.33 (as of Oct 26, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 20, 2026
- Transactions
- 99
- Identified insiders
- 6
- Purchases
- 0
- Sales
- 56
- Other transactions
- 43
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 266 Period end Jun 30, 2026
- Previous quarter · holders
- 187 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 9,057,645 |
| Blackrock, INC. | 4,990,181 |
| Venrock Adviser, LLC | 4,148,428 |
| Fairmount Funds Management LLC | 3,705,262 |
| Capital World Investors | 3,401,639 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Oruka Therapeutics (ORKA)?
Oruka Therapeutics Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Oruka’s dual interleukin A and F antibody address?
The candidate is designed to target the A and F forms of an interleukin and is being developed for psoriasis, psoriatic arthritis, and other conditions. With no product revenue and research spending dominating the accounts, its significance rests on clinical progress rather than current sales.
Why is Oruka’s sequential antibody regimen important?
The regimen extends Oruka’s strategy beyond standalone antibodies by using its dual interleukin program and its p-subunit program sequentially. It broadens the development approach within the same inflammatory-disease portfolio, but no commercial revenue is expected across most of the forecast horizon.
Can Oruka fund its psoriasis antibody programs from current liquidity?
Current cash and investments are large relative to debt, and the recent burn rate implies substantial funding capacity. Rising research expense and operating cash use still matter because continued acceleration would shorten that runway.
Why does Oruka report losses without medicine sales?
Oruka is spending to develop clinical-stage antibodies before generating product revenue. The latest increase in research expense widened the operating loss and coincided with heavier operating cash use.
What is the ORKA stock price today?
The last price recorded on this page for Oruka Therapeutics, Inc. (ORKA) is $90.33, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ORKA price target?
The analyst consensus price target for Oruka Therapeutics, Inc. (ORKA) is $144.56 (range $120.00 to $200.00, median $130.00), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (66 figures)
The 66 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 855 OAK Grove AVE., Suite 100, Menlo Park, CA, 94025 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "855 Oak Grove Avenue, Menlo Park, CA, 94025, US". |
FMP — 56 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 11, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $90.33 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T20:54:38.486Z. | |
px.change | Change on the day | +12.70% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.98B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T20:00:00.000Z. Captured from FMP at 2026-10-26T20:54:37.609Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$10.18 | FMP | Financial Modeling Prep (FMP) · quote | |
px.range52 | 52-week range | $25.23–$115.52 | FMP | Financial Modeling Prep (FMP) quote | |
px.volume | Shares traded on the day | 1.94M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | -0.39 | FMP | Financial Modeling Prep (FMP) company profile | |
id.business_summary | Business description (FMP excerpt) | Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
id.ceo | Chief executive | Lawrence Otto Klein | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 68 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $0.00, net result −$19.32M; FY2022 revenue $0.00, net result −$9.93M; FY2023 revenue $0.00, net result −$5.34M; FY2024 revenue $0.00, net result −$83.72M; FY2025 revenue $0.00, net result −$105.43M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $43.26M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $6.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$50.11M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $29.14M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $7.25M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$36.43M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $27.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $6.76M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$34.43M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $28.99M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $5.12M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$34.10M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-10.eps_actual | EPS · reported — report date 2026-08-10 | −$0.5500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.eps_estimated | EPS · estimate — report date 2026-08-10 | −$0.5125 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.eps_actual | EPS · reported — report date 2026-05-13 | −$0.4800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-13.eps_estimated | EPS · estimate — report date 2026-05-13 | −$0.5469 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-12.eps_actual | EPS · reported — report date 2026-03-12 | −$0.4500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-12.eps_estimated | EPS · estimate — report date 2026-03-12 | −$0.6100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.eps_actual | EPS · reported — report date 2025-11-12 | −$0.5500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.eps_estimated | EPS · estimate — report date 2025-11-12 | −$0.5600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.cash_investments | Cash and short-term investments | $873.56M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$33.15M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $252.02M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $2.55M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 4.52× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$33.15M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$23.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$70,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$22.59M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$60,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$21.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$100,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $120.00 – $200.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $144.56 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $130.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 99 transactions · 0 purchases, 56 sales, 43 other transactions · 6 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Oct 20, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 266 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 187 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 9,057,645 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Blackrock, INC. — shares in provider snapshot | 4,990,181 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Venrock Adviser, LLC — shares in provider snapshot | 4,148,428 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Fairmount Funds Management LLC — shares in provider snapshot | 3,705,262 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Capital World Investors — shares in provider snapshot | 3,401,639 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -20.8% · ROA -11.7% · current ratio 38.51 · earnings yield -2.9% · free-cash-flow yield -2.1% | — | UNRECORDED | Stored key metrics — Date unknown |
fin.scores | Distress and quality screens | Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-26 | |
earn.est_eps | EPS estimate, FY2026 | $-2.40 | UNRECORDED | Stored analyst estimates — Captured 2026-09-26 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $0.00 | UNRECORDED | Stored analyst estimates — Captured 2026-09-26 · Expired observation |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 6.85× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $873.56M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-26. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-10.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.5500) with the recorded estimate (−$0.5125) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 66 of 100 · Strong · pillars 51 / 95 / 56 / 12 / 88 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 66 (stored snapshot Oct 24, 2026) → 66 (current publication computed Oct 26, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-10. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-10.eps_actual.comparison,earn.history.depth.2026-08-10.eps_actual,earn.history.depth.2026-08-10.eps_estimated,earn.history.depth.2026-05-13.eps_actual,earn.history.depth.2026-05-13.eps_estimated,earn.history.depth.2026-03-12.eps_actual,earn.history.depth.2026-03-12.eps_estimated,earn.history.depth.2025-11-12.eps_actual,earn.history.depth.2025-11-12.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
At most 3 analysts contributed — treat this as thin coverage, not a consensus. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Cash, investments and debt | Total debt: $2.55M; Liquidity basis: cash and short-term investments; Total liabilities: $24.85M; Cash and short-term investments: $873.56M; Cash and investments: $1.13B; Long-term investments: $252.02M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-10 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.13B; Cash and short-term investments: $873.60M; Long-term investments: $252.00M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash runway cross-check (ours) | Years: 8.8; Method: cash and short-term investments of $873.6M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($99.5M per year); Reaches: 2035-04; Cash basis: cash and short-term investments; Cash: $873.60M; Annualized cash use: $99.50M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $871.00M; Total debt: $2.50M; Cash and investments: $873.60M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Next earnings report | Date: 2026-11-11; EPS estimate: -$0.59624 per share The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
Data provided for informational purposes only.